Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Down 83.2% in November

Evoke Pharma, Inc. (NASDAQ:EVOKGet Free Report) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 17,000 shares, a drop of 83.2% from the October 31st total of 101,000 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 379,700 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Evoke Pharma in a research report on Wednesday, November 20th. They issued a “sell” rating on the stock.

Check Out Our Latest Research Report on EVOK

Evoke Pharma Trading Down 0.5 %

Shares of NASDAQ:EVOK traded down $0.02 during midday trading on Wednesday, reaching $4.37. The company had a trading volume of 13,630 shares, compared to its average volume of 125,219. The stock has a market cap of $6.51 million, a P/E ratio of -0.40 and a beta of 0.36. The company’s 50 day moving average price is $5.15 and its 200 day moving average price is $5.43. Evoke Pharma has a 52-week low of $3.54 and a 52-week high of $17.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOKFree Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Further Reading

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.